ClinicalTrials.gg
Status unknownNCT02380625Updated Mar 5, 2015

Multiple Treatments for Ebola Virus Disease (EVD)

A Phase 1/2 interventional study of Azithromycin and Sunitinib and Erlotinib in Ebola Virus Disease, sponsored by Clinical Research Management, Inc.. Status unknown. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2015-03-05.

Sponsored by Clinical Research Management, Inc. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2015), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Study summary

The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)

Read the detailed description

The ongoing epidemic of EVD has ravaged parts of West Africa, with initial cases reported in December 2013. There is no licensed specific therapy for the disease, which has a case-fatality rate of approximately 50-70%. Although anecdotal clinical data, recent studies in animal models, and in vitro screening suggest that treatment of EVD patients with anti-viral agents, immune modifying agents, and/or convalescent blood products may be effective, they have not been evaluated in clinical trials. This multi-arm clinical trial will evaluate the efficacy and safety of multiple regimens, both as mono-therapy and combination therapy. Provision of these regimens, if found effective and safe, would have a major impact on the current and future epidemics by providing effective treatment options.

As described for previous adaptive trials, a randomization probability for each of the treatment regimens is created based on 14-day mortality, and is used for weighting randomization of subsequently enrolled participants. Participants will continually be preferentially assigned to regimens with better initial performance. New agents can be added or existing agents removed as the trial evolves.

02

Conditions studied

  • Ebola Virus Disease

Keywords

  • Ebola
  • EVD
  • Adaptive design
  • therapeutics
03

In context

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

This study's planned enrollment of 150 is above the median of 94 across 81 interventional studies indexed under Hemorrhagic Fever, Ebola.

Browse Hemorrhagic Fever, Ebola studies →

Lead sponsor

Clinical Research Management, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 6 months and >8kg in weight
  • Confirmed case of EVD
  • Admission to the hospital \< 48 hours prior to enrollment
  • Participant or family member/guardian able and willing to provide signed

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any other specific experimental anti-EVD product, or expectation to receive another experimental anti-EVD product during the course of the study (this does not include general supportive care or nutritional supplements routinely administered to all hospitalized patients with EVD)
  • Unresponsive
  • In the treating physicians opinion, an inability to comply with the study treatment regimen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Azithromycin

    Azithromycin, IV fluids and laboratory testing

    Drug: Azithromycin · Other: IV fluids and laboratory testing

  • Experimental
    Sunitinib and Erlotinib

    Sunitinib, Erlotinib, IV fluids and laboratory testing

    Drug: Sunitinib and Erlotinib · Other: IV fluids and laboratory testing

  • Experimental
    Atorvastatin and Irbesartan

    Atorvastatin, Irbesartan, IV fluids and laboratory testing

    Drug: Atorvastatin and Irbesartan · Other: IV fluids and laboratory testing

  • Other
    IV fluids and laboratory testing

    no additional treatment

    Other: IV fluids and laboratory testing

Interventions

  • Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days

    Also known as: Zithromax

  • DrugSunitinib and Erlotinib

    Drug pages: Sunitinib · Erlotinib

    Sunitinib - Adults (\>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (\>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (\>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (\>30kg to \< 18 yrs): 25 mg/kg daily for 7 days

    Also known as: Sutent, Tarceva

  • DrugAtorvastatin and Irbesartan

    Drug pages: Atorvastatin · Irbesartan

    Atorvastatin - Adults (\>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (\>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.

    Also known as: Lipitor, Avapro

  • OtherIV fluids and laboratory testing

    All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.

06

What researchers measure

Primary outcomes

  1. Death by 14 days

    Time frame: 14 days after starting treatment regimen

Secondary outcomes

  1. Reduction in viral load

    Time frame: 14 days after starting treatment regimen

  2. 2-week post discharge clinical sequelae, including signs and symptoms and laboratory abnormalities

    Time frame: 14 days after starting treatment

Other outcomes

  1. Severe adverse events that are inconsistent with EVD and are assessed as related to study agent(s) by the site principal investigator

    Time frame: 14 days after starting treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW. A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response. Clin Trials. 2016 Feb;13(1):22-30. doi: 10.1177/1740774515621721. Epub 2016 Jan 14. PubMed 26768569 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jan 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2015
First posted
Mar 5, 2015
Start
Apr 2015
Primary completionEst.
Jan 2016
CompletionEst.
Mar 2016
Last update
Mar 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02380625
Lead sponsor
Clinical Research Management, Inc.
Collaborators
Bill and Melinda Gates Foundation, Duke University, University of Sierra Leone, Syneos Health, University of North Carolina
Responsible party
Sponsor
First posted
Mar 5, 2015
Start date
Apr 2015
Primary completion
Jan 2016 (estimated)
Completion
Mar 2016 (estimated)
Last update
Mar 5, 2015

Study contacts

John M Griffiss, MD
Contact
crapaud@loursage.org
1-800-431-9640
Christopher W Woods, MD, MPH
Contact
chris.woods@duke.edu
919-668-7174
Christopher Woods, MD, MPH
principal investigator · Duke University
John M Griffiss, MD
study chair · Clinical Research Management
David L Hoover, MD
study chair · Clinical Research Management

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azithromycin · Sunitinib · Erlotinib · Atorvastatin · Irbesartan

Start the discussion